Takeda Report Results of TAK-620 (maribavir) in P-III SOLCTICE Trial for the Treatment of Post-Transplant Patients with Cytomegalovirus Infection

February 15, 2021 Auto Bot Clinical Trials, P-III, patients, Report, results, Takeda, Treatment, Trial 0

Shots:

  • The P-III TAK-620-303 (SOLSTICE) trial involves assessing TAK-620 (400mg) vs conventional antiviral therapies (IAT) in HCT and SOT recipients in a ratio (2:1) with R/R CMV infection refractory with/ out resistance, to one or a combination of the conventional antiviral therapies
  • The 1EPs study shows confirmed CMV viremia clearance @ 8wk; (55% vs 26.1% in SOT recipients), (55.9% vs 20.8% in HCT recipients), CMV clearance regardless of baseline viral load category (62.1% & 43.9% vs 24.7% & 21.9%), CMV viremia clearance and symptom control in transplant recipients @16wks. (18.7% vs 10.3%)
  • The company is committed to advancing the care of vulnerable transplant recipients, and if approved, Maribavir will be the 1st and only treatment indicated for post-transplant r/r cmv infection

Click here ­to­ read full press release/ article | Ref: Takeda | Image: The Boston Globe

The post Takeda Report Results of TAK-620 (maribavir) in P-III SOLCTICE Trial for the Treatment of Post-Transplant Patients with Cytomegalovirus Infection first appeared on PharmaShots.